Emergent Biosolutions (EBS) Misses Q2 EPS by 2c; Mixed Guidance
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.32 -0.83%
Revenue Growth %: +32.0%
Financial Fact:
Interest income: 358K
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: +32.0%
Financial Fact:
Interest income: 358K
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Emergent Biosolutions (NYSE: EBS) reported Q2 EPS of $0.21, $0.02 worse than the analyst estimate of $0.23. Revenue for the quarter came in at $70.4 million versus the consensus estimate of $76.2 million.
Emergent Biosolutions sees FY2012 revenue of $60-$70 million, versus the consensus of $78.32 million.
Emergent Biosolutions sees FY2012 revenue of $280-$300 million, versus the consensus of $292.99 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Emergent Biosolutions sees FY2012 revenue of $60-$70 million, versus the consensus of $78.32 million.
Emergent Biosolutions sees FY2012 revenue of $280-$300 million, versus the consensus of $292.99 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia pitches Vera CPU to Chinese clients with August delivery target
- Sharon AI surges premarket; New Oriental gains, Medline slips
- Medtronic completes $550 million Scientia Vascular acquisition
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
